Approved for use through 07/31/2006 (OMS 055)
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF CONTO!
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unfe

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10599713
Filing Date		2006-10-05
First Named Inventor Charli		KRUSE
Art Unit		
Examiner Name		
Attorney Docket Numb	or	R1180/20064

					U.S.	PATENTS			Remove	
Examiner Initial*	ner Cite No Patent Number Kind Code Issue Date Name of Patentee or Application of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1									
If you wisi	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Applicar of cited Document			Releva	Columns,Lines whe int Passages or Reli s Appear	
	1	20050014254	A1	2005-01	1-20	KRUSE				
If you wisi	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button		
				FOREIG	GN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	т.
	1	02086107	wo		A2	2002-10-31	WOBUS et al.			
	2	2005001073	wo		A1	2005-01-06	KRUSE et al.			
	3	2005001072	wo		A1	2005-01-06	KRUSE			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599713
Filing Date		2006-10-05
First Named Inventor Charli		KRUSE
Art Unit		
Examiner Name		
Attorney Docket Number		B1180/20064

If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
		NON-PATENT LITERATURE DOCUMENTS Remove					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposism, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.					
	1	BACHEM et al., "Identification, Culture, and Characterization of Pancreatic Stellate Cells in Rats and Humans", Gestroenterol., 115421-432 (1998)					
	2	GROSFILS et al., "Isolation of Rat Pancreatic Admi with Crude Collagenase and Permeabilization of These Admi with Streptolysin 0", Res. Comm. Chem. Pathol. Pharmacol., 79:99-115 (1993)					
	3	KRUSE et al., "Purpolency of adult stem cells derived from human and rat pancreas", Appl. Phys. A 79, 1617-1624 (2004)					
	4	MITAKA, "Reconstruction of hepatic organoid by hepatic stem cells", J. Hepatobiliary Pancreat. Surg., 9 697-703 (2002)					
	5	RAMIYA et al., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells", Nature Medione, 6.278-282 (2000)					
	6	International Search Report for PCT/EP2005002313					
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner	Signa	ture Date Considered					

See Knd Codes of USPTO Patent Documents at www.USPTO.GDV or MPEP 801.84. *Enter office that issued the document, by the two-lefer code (WPO Sandard ST 33, **For Japanese pixel documents, the schools or the year of the range of the Engager many practice the serial number of the patent document. The patent social common is serial to the local counter into the WPO Sandard ST 16 patents. *Applicate this patent serial counter into the WPO Sandard ST 16 patents. *Applicate this patent serial counter into the WPO Sandard ST 16 patents. *Applicate this patents.*

Total this patent serial patents are into the total counter into the WPO Sandard ST 16 patents.

**Total this patents are into the patents are

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599713
Filing Date		2006-10-05
First Named Inventor	Charl	KRUSE
Art Unit		
Examiner Name		
Attorney Docket Number		B1180/20064

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate selection(s):	
---------------	----------	----------	-------------	---------------------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

offi of the agricult.								
Signature	/David M. Tener/	Date (YYYY-MM-DD)	2006-12-05					
Name/Print	David M. Tener	Registration Number	37.054					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2213-1450, D. ON TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2213-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.